TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with Greatest Unmet Need for New Treatments

TapImmune, Inc. today announced that, in coordination with the U.S. Food and Drug Administration (FDA), it has amended the patient inclusion criteria for its Phase 2 clinical trial of the Company’s T-cell therapeutic peptide vaccine TPIV200 to focus on women with Stage III and IV ovarian cancer who are in remission following their first round of successful platinum-based chemotherapy. TapImmune has enrolled the first women under this amended study protocol, which significantly expands the population of patients that can be addressed with TPIV 200 as a potential maintenance therapy designed to prevent disease recurrence.

Vaccine could prevent breast, ovarian, lung cancer

It’s a dream many parents would welcome for their children: a vaccine that could prevent breast, ovarian and some lung cancers. It’s also the dream of immunology professor Dr. Keith Knutson. “The hope is we can develop vaccines before the development of cancer much in the way that we use a polio vaccine or a flu vaccine,” Dr. Knutson tells us in in his Mayo Clinic Jacksonville laboratory.

T.L. Williams; TapImmune; 1904 Music Hall

Monday on First Coast Connect we spoke with former CIA operative and author T. L. Williams about his new novel and Chinese cyber hacking. We also heard from TapImmune CEO Glynn Wilson about a breast cancer study at the Mayo Clinic. WJCT’s Indie Endeavor host Ryan Benk and 1904 Music Hall co-owner Jason Hunnicut announced a new partnership at the downtown venue.